Jerini starts angioedema Phase II

Jerini (Berlin, Germany) began a Phase II trial of Icatibant in patients with acute attacks of angioedema. Icatibant is a selective peptidomimetic bradykinin BK 2 receptor antagonist licensed from Ave...